The level of autoantibodies against oxidized LDL, is not associated with the presence of coronary heart disease or diabetic kidney disease in patients with non-insulin-dependent diabetes mellitus

Free Radical Research

Volumn 29, Issue 2, 1998, Pages 137-141

  Leinonen, Janne S ^a,b,c   Rantalaiho, Vappu ^b   Laippala, Pekka ^d   Wirta, Ole ^b   Pasternack, Amos ^b   Alho, Hannu ^c,e   Jaakkola, Olli ^a,b   Ylä Herttuala, Seppo ^f   Koivula, Timo ^b   Lehtimäki, Terho ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITY OF TAMPERE   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Coronary disease; Diabetes mellitus; LDL cholesterol; Lipoproteins; Non insulindependent; Oxidative stress

Indexed keywords

ALBUMIN; AUTOANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; GLOMERULUS FILTRATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL; URINARY EXCRETION;

EID: 7344236277     PISSN: 10715762     EISSN: None     Source Type: Journal    
DOI: 10.1080/10715769800300151A     Document Type: Article

References (22)

1. W.B. Kannel and D.L. McGee. (1979) Diabetes and cardiovascular disease: the Framingham study. Journal of the American Medical Association, 241, 2035-2038.
2. K. Pyörälä, M. Laakso and M. Uusitupa. (1987) Diabetes and atherosclerosis: an epidemiologic view. Diabetes & Metabolism Reviews, 3, 463-524.
3. S. Parthasarathy, D. Steinberg and J.L. Witztum. (1992) The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annual Reviews of Medicine, 43, 219-225.
4. A. Kramer-Guth, T. Quaschning, S. Greiber and C. Wanner. (1996) Potential role of lipids in the progression of diabetic nephropathy. Clinical Nephrology, 46, 262-265.
5. W. Palinski, M.E. Rosenfeld, S. Ylä-Herttuala, G.C. Gurtner, S.S. Socher, S.W. Butler, S. Parthasarathy, T.E. Carew, D. Steinberg and J.L. Witztum. (1989) Low density lipoprotein undergoes oxidative modification in vivo. Proceedings of the National Academy of Sciences of USA, 86, 1372-1376.
6. S. Ylä-Herttuala, W. Palinski, M.E. Rosenfeld, S. Parthasarathy, T.E. Carew, S. Butler, J.L. Witztum and D. Steinberg. (1989) Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. Journal of Clinical Investigation, 84, 1086-1095.
7. J.T. Salonen, S. Ylä-Herttuala, R. Yamamoto, S. Butler, H. Korpela, R. Salonen, K. Nyyssönen, W. Palinski and J.L. Witztum. (1992) Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet, 339, 883-887.
8. M. Puurunen, M. Mänttari, V. Manninen, L. Tenkanen, G. Alfthan, C. Ehnholm, O. Vaarala, K. Aho and T. Palosuo. (1994) Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Archives of Internal Medicine, 154, 2605-2609.
9. G. Bellomo, E. Maggi, M. Poli, F.G. Agosta, P. Bollati and G. Finardi. (1995) Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes, 44, 60-66.
10. M.I. Uusitupa, L. Niskanen, J. Luoma, P. Vilja, M. Mercuri, R. Rauramaa and S. Ylä-Herttuala. (1996) Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arteriosclerosis, Thrombosis & Vascular Biology, 16, 1236-1242.
11. O. Wirta, A. Pasternack, P. Laippala and V. Turjanmaa. (1996) Glomerular filtration rate and kidney size after six years disease duration in non-insulin-dependent diabetic subjects. Clinical Nephrology, 45, 10-17.
12. WHO expert committee on diabetes mellitus. (1980) The second report: 646. Technical report series. World Health Organization, Geneva.
13. G.A. Rose and H. Blackburn. (1968) Cardiovascular survey methods. World Health Organization Monograph Series, 56, 1-188.
14. G.R. Warnick, J. Benderson and J.J. Albers. (1983) In: G.R. Cooper, ed. Selected Methods of Clinical Chemistry, American Association for Clinical Chemistry, 91-99.
15. W.T. Friedewald, R.I. Levy and D.S. Fredrickson. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry, 18, 499-502.
16. E.S. Garnett, V. Parsons and N. Veall. (1967) Measurement of glomerular filtration-rate in man using a 51Cr-edeticacid complex. Lancet, 1, 818-819.
17. D. Giugliano, A. Ceriello and G. Paolisso. (1996) Oxidative stress and diabetic vascular complications. Diabetes Care, 19, 257-267.
18. M.F. Lopes-Virella, R.L. Klein and G. Virella. (1996) Modification of lipoproteins in diabetes. Diabetes/Metabolism Reviews, 12, 69-90.
19. E. Korpinen, P.H. Groop, H.K. Åkerblom and O. Vaarala. (1997) Immune response to glycated and oxidized LDL in IDDM patients with and without renal disease. Diabetes Care, 20, 1168-1171.
20. R.K. Sundaram, A. Bhaskar, S. Vijayalingam, M. Viswanathan, R. Mohan and K.R. Shanmugasundaram. (1996) Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications. Clinical Science, 90, 255-260.
21. G. Gallou, A. Ruelland, B. Legras, D. Maugendre, H. Allannic and L. Cloarec. (1993) Plasma malondialdehyde in type 1 and type 2 diabetic patients. Clinica Chimica Acta, 214, 227-234.
22. E. Velazquez, P.H. Winocour, P. Kesteven, K.G. Alberti and M.F. Laker. (1991) Relation of lipid peroxides to macrovascular disease in type 2 diabetes. Diabetic Medicine, 8, 752-758.